stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Gross margin
Spyre Therapeutics, Inc.'s gross margin over the twelve months to 31 December 2023 was 100.0%. Over the past ten years it has ranged from 0.00% (fiscal 2020) to 100.0% (fiscal 2023) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2023 | 100.0% | 0.00 |
| FY2022 | 100.0% | 0.00 |
| FY2021 | 100.0% | 100.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | (100.00) |
| FY2018 | 100.0% | 0.00 |
| FY2017 | 100.0% | 0.00 |
| FY2016 | 100.0% | 0.00 |
| FY2015 | 100.0% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Dec 2023 | 0.00% | (100.00) |
| Jun 2023 | 100.0% | 0.00 |
| Mar 2023 | 100.0% | 0.00 |
| Dec 2022 | 100.0% | 0.00 |
| 25 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 100.0% |
| SYRE Spyre Therapeutics, Inc. | 100.0% |
| IBRX ImmunityBio, Inc. compare | 99.3% |
| KRYS Krystal Biotech, Inc. compare | 94.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 91.0% |
| TGTX TG Therapeutics, Inc. compare | 82.4% |
| TWST Twist Bioscience Corporation compare | 52.0% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement